CORE
CO
nnecting
RE
positories
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Research partnership
About
About
About us
Our mission
Team
Blog
FAQs
Contact us
Community governance
Governance
Advisory Board
Board of supporters
Research network
Innovations
Our research
Labs
research
SAHA-induced TRAIL-sensitisation of Multiple Myeloma cells is enhanced in 3D cell culture
Authors
A. Arhoma
A.D. Chantry
+31 more
Abdulghani
Al-Yacoub
Amatangelo
Bladé
Deleu
Doi
Fandy
Fischbach
Geng
Herbst
Hideshima
Jelinek
Jian
Kagawa
Le Maitre
Lemancewicz
Matsui
Matthews
McStay
N.A. Cross
Niesvizky
Pan
Peterson
Rosato
S.L. Haywood-Small
Vitovski
von Pawel
Xu
Yamada
Younes
Zaravinos
Publication date
8 September 2017
Publisher
'Elsevier BV'
Doi
Cite
Abstract
Multiple Myeloma (MM) is currently incurable despite many novel therapies. Tumour Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) is a potential anti-tumour agent although effects as a single agent are limited. In this study, we investigated whether the Histone Deacetylase (HDAC) inhibitor SAHA can enhance TRAIL-induced apoptosis and target TRAIL resistance in both suspension culture, and 3D cell culture as a model of disseminated MM lesions that form in bone. The effects of SAHA and/or TRAIL in 6 Multiple Myeloma cell lines were assessed in both suspension cultures and in an Alginate-based 3D cell culture model. The effect of SAHA and/or TRAIL was assessed on apoptosis by assessment of nuclear morphology using Hoechst 33342/Propidium Iodide staining. Viable cell number was assessed by CellTiter-Glo luminescence assay, Caspase-8 and -9 activities were measured by Caspase-Glo™ assay kit. TRAIL-resistant cells were generated by culture of RPMI 8226 and NCI-H929 by acute exposure to TRAIL followed by selection of TRAIL-resistant cells. TRAIL significantly induced apoptosis in a dose-dependent manner in OPM-2, RPMI 8226, NCI-H929, U266, JJN-3 MM cell lines and ADC-1 plasma cell leukaemia cells. SAHA amplified TRAIL responses in all lines except OPM-2, and enhanced TRAIL responses were both via Caspase-8 and -9. SAHA treatment induced growth inhibition that further increased in the combination treatment with TRAIL in MM cells. The co-treatment of TRAIL and SAHA reduced viable cell numbers all cell lines. TRAIL responses were further potentiated by SAHA in 3D cell culture in NCI-H929, RPMI 8226 and U266 at lower TRAIL + SAHA doses than in suspension culture. However TRAIL responses in cells that had been selected for TRAIL resistance were not further enhanced by SAHA treatment. SAHA is a potent sensitizer of TRAIL responses in both TRAIL sensitive and resistant cell lines, in both suspension and 3D culture, however SAHA did not sensitise TRAIL-sensitive cell populations that had been selected for TRAIL-resistance from initially TRAIL-sensitive populations. SAHA may increase TRAIL sensitivity in insensitive cells, but not in cells that have specifically been selected for acquired TRAIL-resistance. [Abstract copyright: Copyright © 2017 Elsevier Inc. All rights reserved.
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Sheffield Hallam University Research Archive
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:shura.shu.ac.uk:16826
Last time updated on 19/10/2017
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
info:doi/10.1016%2Fj.yexcr.201...
Last time updated on 24/10/2020